Anti-influenza A virus activity and structure–activity relationship of a series of nitrobenzoxadiazole derivatives

References

• Shaw ML, Palese P, Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013: 1671–1740.
   Google Scholar
• Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008;66:655–63.
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Belser JA. Resurrected pandemic influenza viruses. Annu Rev Microbiol 2009;63:79–98.
   PubMed Web of Science ®Google Scholar
• Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931–9.
   PubMed Web of Science ®Google Scholar
• Fraser C, The WHO Rapid Pandemic Assessment Collaboration, Donnelly CA, Cauchemez S, et al. Pandemic potential of a strain of influenza a (H1N1): early findings. Science 2009;324:1557–61.
   PubMed Web of Science ®Google Scholar
• Trifonov V, Khiabanian H, Rabadan R. Geographic dependence, surveillance, and origins of the 2009 influenza a (H1N1) virus. N Engl J Med 2009;361:115–9.
   PubMed Web of Science ®Google Scholar
• Das K. Antivirals targeting influenza a virus. J Med Chem 2012;55:6263–77.
   PubMed Web of Science ®Google Scholar
• Syrjänen RK, Jokinen J, Ziegler T, et al. Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009–2010 and 2010–2011 in Finland. PLOS One 2014;9:e108538.
   PubMed Web of Science ®Google Scholar
• Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964;144:862–3.
   PubMed Web of Science ®Google Scholar
• Cady SD, Schmidt-Rohr K, Wang J, et al. Structure of the amantadine binding site of influenza m2 proton channels in lipid bilayers. Nature 2010;463:689–92.
   PubMed Web of Science ®Google Scholar
• Pielak RM, Chou JJ. Flu channel drug resistance: a tale of two sites. Protein Cell 2010;1:246–58.
   PubMed Web of Science ®Google Scholar
• Jing X, Ma C, Ohigashi Y, et al. Functional studies indicate amantadine binds to the pore of the influenza a virus m2 proton-selective ion channel. Proc Natl Acad Sci USA 2008;105:10967–72.
   PubMed Web of Science ®Google Scholar
• von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418–23.
   PubMed Web of Science ®Google Scholar
• Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997;119:681–90.
   PubMed Web of Science ®Google Scholar
• Stevaert A, Naesens L. The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design. Med Res Rev 2016;36:1127–73.
   PubMed Web of Science ®Google Scholar
• Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 2018;160:109–17.
   PubMed Web of Science ®Google Scholar
• Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020;209:107512.
   PubMed Web of Science ®Google Scholar
• Shionogi. Shionogi announces supplemental new drug application for XOFLUZA® in Japan for the post-exposure prophylaxis of influenza virus infection was approved [Internet]. ; 2020, November 27 [cited 2021 Jul 27]. Available from: https://www.shionogi.com/content/dam/shionogi/global/news/pdf/2020/11/e-201127.pdf
   Google Scholar
• Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau – Ministry of Health, Labour and Welfare. Report on the deliberation results [Internet]. 2018, February 8 [cited 2021 ]. Available from: https://www.pmda.go.jp/files/000225380.pdf
   Google Scholar
• U. S. Food & Drug Administration. FDA approves new drug to treat influenza [Internet]. 2018, October 24 [cited 2021 Jul 27]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza
   Google Scholar
• U. S. Food & Drug Administration. FDA expands approval of influenza treatment to post-exposure prevention [Internet]. 2020, November 23 [cited 2021 Jul 27]. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-influenza-treatment-post-exposure-prevention
   Google Scholar
• European Medicines Agency. Xofluza [Internet].2021, January 22 [cited 2021 Jul 27]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza
   Google Scholar
• Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau – Ministry of Health, Labour and Welfare. Report on the deliberation results [Internet]. 2014, March 4 [cited 2021 Jul 27]. Available from: https://www.pmda.go.jp/files/000210319.pdf
   Google Scholar
• Kessler U, Castagnolo D, Pagano M, et al. Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza a virus. Bioorg Med Chem Lett 2013;23:5575–7.
   PubMed Web of Science ®Google Scholar
• Pagano M, Castagnolo D, Bernardini M, et al. The fight against the influenza a virus H1N1: Synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral rna polymerase inhibitors. ChemMedChem 2014;9:129–50.
   PubMed Web of Science ®Google Scholar
• Ricci G, De Maria F, Antonini G, et al. 7-nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione s-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem 2005;280:26397–405.
   PubMed Web of Science ®Google Scholar
• Rotili D, De Luca A, Tarantino D, et al. Synthesis and structure-activity relationship of new cytotoxic agents targeting human glutathione-s-transferases. Eur J Med Chem 2015;89:156–71.
   PubMed Web of Science ®Google Scholar
• Graziani G, Artuso S, De Luca A, et al. A new water soluble mapk activator exerts antitumor activity in melanoma cells resistant to the braf inhibitor vemurafenib. Biochem Pharmacol 2015;95:16–27.
   PubMed Web of Science ®Google Scholar
• Sciarretta F, Fulci C, Palumbo C, et al. Effects of glutathione transferase-targeting nitrobenzoxadiazole compounds in relation to pd-l1 status in human melanoma cells. Chemotherapy 2019;64:138–45.
   PubMed Web of Science ®Google Scholar
• De Luca A, Carpanese D, Rapanotti MC, et al. The nitrobenzoxadiazole derivative mc3181 blocks melanoma invasion and metastasis. Oncotarget 2017;8:15520–38.
   PubMedGoogle Scholar
• Palumbo C, De Luca A, Rosato N, et al. C-jun n-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition. J Transl Med 2016;14:37.
   PubMed Web of Science ®Google Scholar
• Tew KD, Monks A, Barone L, et al. Glutathione-associated enzymes in the human cell lines of the national cancer institute drug screening program. Mol Pharmacol 1996;50:149–59.
   PubMed Web of Science ®Google Scholar
• Ruiz-Gómez MJ, Souviron A, Martínez-Morillo M, Gil L. P-glycoprotein, glutathione and glutathione s-transferase increase in a colon carcinoma cell line by colchicine. J Physiol Biochem 2000;56:307–12.
   PubMed Web of Science ®Google Scholar
• Inoue T, Ishida T, Sugio K, et al. Glutathione s transferase pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 1995;62:223–7.
   PubMed Web of Science ®Google Scholar
• Checconi P, Sgarbanti R, Celestino I, et al. The environmental pollutant cadmium promotes influenza virus replication in mdck cells by altering their redox state. Int J Mol Sci 2013;14:4148–62.
   PubMed Web of Science ®Google Scholar
• Fioravanti R, Celestino I, Costi R, et al. Effects of polyphenol compounds on influenza a virus replication and definition of their mechanism of action. Bioorg Med Chem 2012;20:5046–52.
   PubMed Web of Science ®Google Scholar
• De Angelis M, Casciaro B, Genovese A, et al. Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: insights into biological activity and mechanism of action. Faseb J 2021;35:e21358.
   PubMed Web of Science ®Google Scholar
• De Luca A, Rotili D, Carpanese D, et al. A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. Oncotarget 2015;6:4126–43.
   PubMed Web of Science ®Google Scholar
• Fulci C, Rotili D, De Luca A, et al. A new nitrobenzoxadiazole-based gstp1-1 inhibitor with a previously unheard of mechanism of action and high stability. J Enzyme Inhib Med Chem 2017;32:240–7.
   PubMed Web of Science ®Google Scholar
• Di Paolo V, Fulci C, Rotili D, et al. Characterization of water-soluble esters of nitrobenzoxadiazole-based gstp1-1 inhibitors for cancer treatment. Biochem Pharmacol 2020;178:114060.
   PubMed Web of Science ®Google Scholar
• Marcocci ME, Amatore D, Villa S, et al. The amphibian antimicrobial peptide temporin b inhibits in vitro herpes simplex virus 1 infection. Antimicrob Agents Chemother 2018;62:e02367–02317.
   PubMed Web of Science ®Google Scholar